Comparison of Outcome Between Oral Methotrexate and Tofacitinib in Treatment of Chronic Plaque Psoriasis

Pak Emirates Military Hospital0 个研究点目标入组 88 人开始时间: 2026年6月1日最近更新: 2026年5月12日

试验速览

阶段: 不适用
状态: 尚未招募
发起方
入组人数: 88

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

This randomized controlled trial aims to compare the efficacy and safety of oral methotrexate and tofacitinib in patients with chronic plaque psoriasis. Participants diagnosed with chronic plaque psoriasis will be randomly assigned to receive either methotrexate or tofacitinib and will be followed for six months. Clinical improvement, disease severity, treatment response, and adverse effects will be assessed and compared between the two treatment groups.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 70 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Eligible participants will comprise adults aged 18 to 70 years, of either gender, with moderate to severe plaque psoriasis defined by a Psoriasis Area and Severity Index (PASI) score greater than
•A minimum disease duration of 6 months will be required. In addition, enrolment will be limited to patients whose psoriasis has shown inadequate response to at least one topical therapy despite a treatment duration of at least 4 weeks

排除标准

•Participants with non-plaque variants of psoriasis or any other clinically significant dermatological condition that could confound the assessment of psoriasis severity. Recent exposure to anti psoriatic therapy including systemic or biologic treatment within the preceding 4 weeks or topical treatment within the preceding 2 weeks. Individuals with known hypersensitivity to, or contraindications for, either methotrexate or tofacitinib. Patients with a history of significant hepatic, renal, hematologic, gastrointestinal, or immune system disorders. Pregnant or breastfeeding women. Patients unavoidable prolonged sun or ultraviolet exposure. Patients with a history of alcohol abuse, or other conditions that contraindicate methotrexate use..

研究者

发起方

Pak Emirates Military Hospital

申办方类型

Other

责任方

Principal Investigator

主要研究者

Aimen Umar Luk

Resident Dermatology

Pak Emirates Military Hospital

相似试验

尚未招募

4 期

Methotrexate Versus Apremilast for Pruritus in PsoriasisPruritus

NCT07432386Zarmeen Khawar80

进行中（未招募）

4 期

The Value of Methotrexate in NCES for Stable Vitiligo

NCT07352293Cairo University20

尚未招募

3 期

A study to assess the efficacy of methotrexate with metformin in the treatment of chronic plaque psoriasis with metabolic syndrome

CTRI/2024/08/072788Dr.Deepa. K70

尚未招募

4 期

Comparing Treatment out come of psoriasis with Oral Methotraxate versus Oral Tofacitinib

CTRI/2024/08/072427Rishana N96

招募中

4 期

The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial

2024-514055-15-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)132